SAN DIEGO--(BUSINESS WIRE)--Apr. 8, 2013--      Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results      for first quarter 2013 following the close of market on Monday, April      22, 2013.    
      On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time), Jay      Flatley, President and Chief Executive Officer, Marc Stapley, Senior      Vice President and Chief Financial Officer, and Christian Henry, Senior      Vice President and General Manager, Genomic Solutions, will host a      conference call with analysts, investors, and other interested parties      to discuss financial and operating results.    
      Conference Call Details    
      The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern      Time) on Monday, April 22, 2013. Interested parties may listen to the      call by dialing 888.679.8033 (passcode: 58226131), or if outside North      America, by dialing +1.617.213.4846 (passcode: 58226131). Individuals      may access the live teleconference in the Investor Relations section of      Illumina's web site under the “Company” tab at www.illumina.com.    
      A replay of the conference call will be available from 4:00 pm Pacific      Time (7:00 pm Eastern Time) on April 22, 2013 through April 29, 2013 by      dialing 888.286.8010 (passcode: 31374623), or if outside North America,      by dialing +1.617.801.6888 (passcode: 31374623).    
      About Illumina    
      Illumina (http://www.illumina.com)      is a leading developer, manufacturer, and marketer of life science tools      and integrated systems for the analysis of genetic variation and      function. We provide innovative sequencing and array-based solutions for      genotyping, copy number variation analysis, methylation studies, gene      expression profiling, and low-multiplex analysis of DNA, RNA, and      protein. We also provide tools and services that are fueling advances in      consumer genomics and diagnostics. Our technology and products      accelerate genetic analysis research and its application, paving the way      for molecular medicine and ultimately transforming healthcare.    

Source: Illumina, Inc.
      Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer      Temple
858-882-6822
pr@illumina.com